Cancel anytime
Brainsway Ltd (BWAY)BWAY
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/08/2024: BWAY (3-star) is a STRONG-BUY. BUY since 113 days. Profits (72.66%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Regular Buy |
Historic Profit: 267.29% | Upturn Advisory Performance 4 | Avg. Invested days: 53 |
Profits based on simulation | Stock Returns Performance 5 | Last Close 11/08/2024 |
Type: Stock | Today’s Advisory: Regular Buy |
Historic Profit: 267.29% | Avg. Invested days: 53 |
Upturn Star Rating | Stock Returns Performance 5 |
Profits based on simulation Last Close 11/08/2024 | Upturn Advisory Performance 4 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 181.12M USD |
Price to earnings Ratio 543 | 1Y Target Price 12.78 |
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Volume (30-day avg) 105996 | Beta 0.37 |
52 Weeks Range 3.80 - 10.89 | Updated Date 11/10/2024 |
Company Size Small-Cap Stock | Market Capitalization 181.12M USD | Price to earnings Ratio 543 | 1Y Target Price 12.78 |
Dividends yield (FY) - | Basic EPS (TTM) 0.02 | Volume (30-day avg) 105996 | Beta 0.37 |
52 Weeks Range 3.80 - 10.89 | Updated Date 11/10/2024 |
Earnings Date
Report Date 2024-11-13 | When BeforeMarket |
Estimate 0.01 | Actual - |
Report Date 2024-11-13 | When BeforeMarket | Estimate 0.01 | Actual - |
Profitability
Profit Margin 1.67% | Operating Margin (TTM) 5.86% |
Management Effectiveness
Return on Assets (TTM) 0.73% | Return on Equity (TTM) 1.44% |
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE 543 | Forward PE 80.65 |
Enterprise Value 129336078 | Price to Sales(TTM) 4.97 |
Enterprise Value to Revenue 3.55 | Enterprise Value to EBITDA 46.46 |
Shares Outstanding 16678100 | Shares Floating 22272600 |
Percent Insiders - | Percent Institutions 19 |
Trailing PE 543 | Forward PE 80.65 | Enterprise Value 129336078 | Price to Sales(TTM) 4.97 |
Enterprise Value to Revenue 3.55 | Enterprise Value to EBITDA 46.46 | Shares Outstanding 16678100 | Shares Floating 22272600 |
Percent Insiders - | Percent Institutions 19 |
Analyst Ratings
Rating 4.75 | Target Price 8.63 | Buy 1 |
Strong Buy 3 | Hold - | Sell - |
Strong Sell - |
Rating 4.75 | Target Price 8.63 | Buy 1 | Strong Buy 3 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Brainsway Ltd. (BWAY) Stock Overview
Company Profile:
History and Background:
Brainsway Ltd. (BWAY) is a commercial-stage medical technology company founded in 2003, headquartered in Jerusalem, Israel. They specialize in the development and commercialization of non-invasive neuromodulation treatments for neurological and psychiatric disorders.
Core Business Areas:
Brainsway's primary business areas consist of:
- Deep Transcranial Magnetic Stimulation (dTMS): This technology delivers magnetic pulses to specific brain regions to modulate neural activity.
- Deep Transcranial Direct Current Stimulation (tDCS): This method utilizes weak electrical currents to modulate brain activity.
Leadership Team and Corporate Structure:
- CEO: Dr. Christopher von Jako
- CFO: Mr. Michael Singer
- Chairman: Ziv Saphier
Brainsway has a Board of Directors and a Management Team overseeing its operations.
Top Products and Market Share:
Top Products:
- Deep TMS System: Cleared by the FDA for the treatment of Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD).
- Deep tDCS System: Cleared by the FDA for the treatment of MDD.
Market Share:
Brainsway holds a significant market share in the dTMS space for MDD treatment, estimated to be around 30% in the US. The global market share for dTMS in OCD treatment is smaller, but Brainsway is a leading player.
Competitor Comparison:
Brainsway competes with other companies offering neuromodulation therapies, such as MagVenture (MAGS) and Neuronetics (STIM). While MagVenture offers similar dTMS systems, Neuronetics focuses on transcranial magnetic stimulation for depression treatment.
Total Addressable Market:
The global market for neuromodulation therapies is expected to reach $12.4 billion by 2027. The MDD treatment market alone is estimated to be around $5.4 billion.
Financial Performance:
Financials:
Brainsway's recent financials have shown revenue growth, but the company remains unprofitable. Their latest earnings report (Q3 2023) showed:
- Revenue: $14.2 million (YoY increase of 21%)
- Net Loss: $10.4 million
- EPS: -$0.27
Cash Flow and Balance Sheet:
Brainsway has negative operating cash flow and relies on external financing for its operations. The company's cash and equivalents stood at $12.4 million as of September 30, 2023.
Dividends and Shareholder Returns:
Dividends:
Brainsway does not currently pay dividends as they reinvest their earnings into growth initiatives.
Shareholder Returns:
BWAY stock has seen significant volatility, declining by over 40% in the past year. However, long-term investors have experienced positive returns, with the stock price appreciating over 200% in the past three years.
Growth Trajectory:
Historical Growth:
Brainsway has shown consistent revenue growth in recent years, driven by increasing adoption of its dTMS technology for MDD and OCD treatment.
Future Growth:
Brainsway's future growth prospects are tied to its continued market penetration in the MDD and OCD treatment markets. They are also exploring other potential applications for their dTMS technology, including PTSD, stroke rehabilitation, and addiction treatment.
Market Dynamics:
Industry Trends:
The neuromodulation market is expected to experience strong growth due to rising awareness of mental health disorders and increasing demand for non-invasive treatments.
Competitive Landscape:
Brainsway faces competition from other neuromodulation companies, both established players and emerging startups. The market is becoming increasingly competitive, with companies vying for market share.
Competitors:
- MagVenture (MAGS)
- Neuronetics (STIM)
- ElectroCore (ECOR)
- Magstim (MSTMY)
Potential Challenges and Opportunities:
Challenges:
- Competition from established players and new entrants.
- Regulatory approvals for new applications of dTMS technology.
- Reimbursement challenges from insurance companies.
Opportunities:
- Expansion into new markets, such as China and Japan.
- Development of new treatment applications for dTMS.
- Strategic partnerships with healthcare providers and pharmaceutical companies.
Recent Acquisitions:
Brainsway has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Rating: 7/10
Justification:
Brainsway has a strong product offering and operates in a growing market with significant potential. The company is also demonstrating revenue growth, despite not yet being profitable. However, competition is increasing, and the company faces challenges with reimbursement and regulatory approval.
Sources and Disclaimers:
This information was gathered from various sources, including Brainsway's website, SEC filings, financial news articles, and industry reports. The information provided here is for educational purposes only and should not be considered investment advice. It is essential to conduct thorough research and consult with a qualified professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Brainsway Ltd
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 1999-10-06 | CEO | - |
Sector | Healthcare | Website | https://www.brainsway.com |
Industry | Medical Devices | Full time employees | 134 |
Headquaters | - | ||
CEO | - | ||
Website | https://www.brainsway.com | ||
Website | https://www.brainsway.com | ||
Full time employees | 134 |
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.